{"id":"NCT03086486","sponsor":"Global Alliance for TB Drug Development","briefTitle":"Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis","officialTitle":"A Phase 3 Partially-blinded, Randomized Trial Assessing the Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary Infection of Either Extensively Drug-resistant Tuberculosis (XDR-TB), Pre-XDR-TB or Treatment Intolerant or Non-responsive Multi-drug Resistant Tuberculosis (MDR-TB)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-11-21","primaryCompletion":"2021-02-15","completion":"2022-02-08","firstPosted":"2017-03-22","resultsPosted":"2023-06-29","lastUpdate":"2023-06-29"},"enrollment":181,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Tuberculosis, Pulmonary","Tuberculosis, Multidrug-Resistant","Tuberculosis, MDR","Tuberculosis","Extensively Drug-Resistant Tuberculosis","Pre-XDR-TB","XDR-TB"],"interventions":[{"type":"DRUG","name":"Pretomanid","otherNames":["PA-824","Pa"]},{"type":"DRUG","name":"Linezolid","otherNames":["L","Lin","Zyvox"]},{"type":"DRUG","name":"Bedaquiline","otherNames":["TMC-207","B","Sirturo"]},{"type":"DRUG","name":"Placebo Linezolid","otherNames":[]}],"arms":[{"label":"1200mg L x 26 weeks + Pa + B","type":"EXPERIMENTAL"},{"label":"1200 mg L x 9 weeks + Pa + B","type":"EXPERIMENTAL"},{"label":"600 mg L x 26 weeks + Pa + B","type":"EXPERIMENTAL"},{"label":"600 mg L x 9 weeks + Pa + B","type":"EXPERIMENTAL"}],"summary":"To evaluate the efficacy, safety and tolerability of various doses and durations of linezolid plus bedaquiline and pretomanid after 26 weeks of treatment in participants with either pulmonary XDR-TB, pre-XDR-TB, or treatment intolerant or non-responsive MDR-TB.","primaryOutcome":{"measure":"Incidence of Bacteriologic Failure or Relapse or Clinical Failure (Unfavorables) Through Follow up Until 26 Weeks After the End of Treatment","timeFrame":"26 weeks","effectByArm":[{"arm":"1200mg L x 26 Weeks + Pa + B","deltaMin":41,"sd":null},{"arm":"1200 mg L x 9 Weeks + Pa + B","deltaMin":40,"sd":null},{"arm":"600 mg L x 26 Weeks + Pa + B","deltaMin":41,"sd":null},{"arm":"600 mg L x 9 Weeks + Pa + B","deltaMin":37,"sd":null},{"arm":"Total","deltaMin":159,"sd":null}],"pValues":[]},"eligibility":{"minAge":"14 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":8},"locations":{"siteCount":11,"countries":["Georgia","Moldova","Russia","South Africa"]},"refs":{"pmids":["36053506"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":45},"commonTop":["Peripheral sensory neuropathy","Hepatic enzyme increased","Neutropenia","Transaminases increased","Nausea"]}}